Moberg Pharma AB (publ) (MOBS.XC)
Moberg Pharma AB (publ)
Gustavslundsvägen 42
5th Floor
Bromma 167 51
Sweden
46 8 52 23 07 00
https://www.mobergpharma.se
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 9
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Anna Ljung BA, M.Sc. | Chief Executive Officer | 2.93M | N/D | 1980 |
| Ms. Marie Moberg | Co-Founder | 193.7k | N/D | N/D |
| Mr. Mark Beveridge | Vice President of Finance | N/D | N/D | 1978 |
| Dr. Christina Erixon | Head of Pharmaceutical Development & Operations | N/D | N/D | 1970 |
| Gunilla Wengström | Senior Director of Sales & Marketing | N/D | N/D | N/D |
| Anders Broijersen M.D., Ph.D. | Chief Medical Officer | N/D | N/D | 1964 |
| Mr. Robert Ehrl | Head of Supply | N/D | N/D | 1967 |
Descripción
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
Gestión corporativa
La calificación ISS Governance QuickScore de Moberg Pharma AB (publ) a partir del 1 de junio de 2024 es 8. Las puntuaciones principales son Auditoría: 9; Junta: 8; Derechos del accionista: 4; Compensación: 7.
